158 related articles for article (PubMed ID: 37828833)
1. Influence of Humoral Response Against GnRH, Generated by Immunization with a Therapeutic Vaccine Candidate on the Evolution of Patients with Castration-Sensitive Prostate Adenocarcinoma.
Campal-Espinosa AC; Junco-Barranco JA; Fuentes-Aguilar F; Calzada-Aguilera L; Rivacoba-Betancourt A; Rodríguez-Bueno RH; Bover-Campal AC; Bover-Fuentes EE; González L; de Quesada L; Alvarez A; Garay-Pérez HE
Technol Cancer Res Treat; 2023; 22():15330338231207318. PubMed ID: 37828833
[TBL] [Abstract][Full Text] [Related]
2. Vaccines for control of fertility and hormone dependent cancers.
Talwar GP; Singh O; Pal R; Chatterjee N
Int J Immunopharmacol; 1992 Apr; 14(3):511-4. PubMed ID: 1618603
[TBL] [Abstract][Full Text] [Related]
3. Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer.
Triozzi PL; Bolger GB; Neidhart J; Rinehart JJ; Saleh M; Allen KO; Sellers S; Waddell MJ
Prostate; 2005 Dec; 65(4):316-21. PubMed ID: 16015596
[TBL] [Abstract][Full Text] [Related]
4. mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine.
Buhre JS; Pongracz T; Künsting I; Lixenfeld AS; Wang W; Nouta J; Lehrian S; Schmelter F; Lunding HB; Dühring L; Kern C; Petry J; Martin EL; Föh B; Steinhaus M; von Kopylow V; Sina C; Graf T; Rahmöller J; Wuhrer M; Ehlers M
Front Immunol; 2022; 13():1020844. PubMed ID: 36713457
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02
Berry AA; Gottlieb ER; Kouriba B; Diarra I; Thera MA; Dutta S; Coulibaly D; Ouattara A; Niangaly A; Kone AK; Traore K; Tolo Y; Mishcherkin V; Soisson L; Diggs CL; Blackwelder WC; Laurens MB; Sztein MB; Doumbo OK; Plowe CV; Lyke KE
Malar J; 2019 Jan; 18(1):13. PubMed ID: 30658710
[TBL] [Abstract][Full Text] [Related]
6. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.
Slovin SF; Ragupathi G; Musselli C; Olkiewicz K; Verbel D; Kuduk SD; Schwarz JB; Sames D; Danishefsky S; Livingston PO; Scher HI
J Clin Oncol; 2003 Dec; 21(23):4292-8. PubMed ID: 14645418
[TBL] [Abstract][Full Text] [Related]
7. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
8. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
[TBL] [Abstract][Full Text] [Related]
9. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists.
Bonde TM; Westerberg M; Aly M; Eklund M; Adolfsson J; Bill-Axelson A; Garmo H; Stattin P; Robinson D
Scand J Urol; 2022 Jun; 56(3):169-175. PubMed ID: 35548951
[No Abstract] [Full Text] [Related]
10. Comparative Detection of Immunoglobulin Isotypes and Subclasses against
Borges HDS; Oliveira-Scussel ACM; Oliveira ÂMM; Abdallah VOS; Pajuaba ACAM; Mineo JR
Int J Environ Res Public Health; 2022 Jun; 19(13):. PubMed ID: 35805611
[TBL] [Abstract][Full Text] [Related]
11. Gonadotrophin releasing hormone-based vaccine, an effective candidate for prostate cancer and other hormone-sensitive neoplasms.
Junco JA; Basalto R; Fuentes F; Bover E; Reyes O; Pimentel E; Calzada L; Castro MD; Arteaga N; López Y; Hernández H; Bringas R; Garay H; Peschke P; Bertot J; Guillén G
Adv Exp Med Biol; 2008; 617():581-7. PubMed ID: 18497085
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer.
Noguchi M; Itoh K; Suekane S; Yao A; Suetsugu N; Katagiri K; Yamada A; Yamana H; Noda S
Cancer Sci; 2004 Jan; 95(1):77-84. PubMed ID: 14720331
[TBL] [Abstract][Full Text] [Related]
13. Phage constructs targeting gonadotropin-releasing hormone for fertility control: evaluation in cats.
Johnson AK; Jones RL; Kraneburg CJ; Cochran AM; Samoylov AM; Wright JC; Hutchinson C; Picut C; Cattley RC; Martin DR; Samoylova TI
J Feline Med Surg; 2020 Aug; 22(8):685-695. PubMed ID: 31566070
[TBL] [Abstract][Full Text] [Related]
14. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
15. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
16. Gradual reduction of testosterone using a gonadotropin-releasing hormone vaccination delays castration resistance in a prostate cancer model.
Barranco JA; Millar RP; Fuentes F; Bover E; Pimentel E; Basulto R; Calzada L; Morán R; Rodríguez A; Garay H; Reyes O; Castro MD; Bringas R; Arteaga N; Toudurí H; Rabassa M; Fernández Y; Serradelo A; Hernández E; Guillén GE
Oncol Lett; 2016 Aug; 12(2):963-970. PubMed ID: 27446378
[TBL] [Abstract][Full Text] [Related]
17. Anti-fertility vaccines.
Talwar GP; Raghupathy R
Vaccine; 1989 Apr; 7(2):97-101. PubMed ID: 2665354
[TBL] [Abstract][Full Text] [Related]
18. Humoral immune responses against gonadotropin releasing hormone elicited by immunization with phage-peptide constructs obtained via phage display.
Samoylov A; Cochran A; Schemera B; Kutzler M; Donovan C; Petrenko V; Bartol F; Samoylova T
J Biotechnol; 2015 Dec; 216():20-8. PubMed ID: 26456116
[TBL] [Abstract][Full Text] [Related]
19. Current vaccination strategies for prostate cancer.
Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
[TBL] [Abstract][Full Text] [Related]
20. Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac.
Junco JA; Rodríguez R; Fuentes F; Baladrón I; Castro MD; Calzada L; Valenzuela C; Bover E; Pimentel E; Basulto R; Arteaga N; Cid-Arregui A; Sariol F; González L; Porres-Fong L; Medina M; Rodríguez A; Garay AH; Reyes O; López M; de Quesada L; Alvarez A; Martínez C; Marrero M; Molero G; Guerra A; Rosales P; Capote C; Acosta S; Vela I; Arzuaga L; Campal A; Ruiz E; Rubio E; Cedeño P; Sánchez MC; Cardoso P; Morán R; Fernández Y; Campos M; Touduri H; Bacardi D; Feria I; Ramirez A; Cosme K; Saura PL; Quintana M; Muzio V; Bringas R; Ayala M; Mendoza M; Fernández LE; Carr A; Herrera L; Guillén G
Front Oncol; 2019; 9():49. PubMed ID: 30859088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
